Abstract: A production of a drug, wherein the drug is specific for SH-SY5Y neuroblastoma cancer by loading caffeic acid phenethyl ester (CAPE) to a plurality of microvesicles that a specialized skin cell leaves into a nutrient solution. The objective of the present invention is to provide a cell-specific targeted vesicle development by loading the CAPE to the plurality of microvesicles obtained as a result of culturing and subsequent specialization of a plurality of tissue cells; and to use the CAPE at lower concentrations compared to a state of the art applications to minimize a toxicity of the CAPE to both a plurality of cells other than a plurality of targeted cells and a body.

Abstract: A method of producing a caffeic acid phenethyl ester loaded microvesicular cancer drug targeting SH-SY5Y neuroblastoma cancer. The method includes seeding a plurality of skin stem cells in a medium; enabling the plurality of skin stem cells in the medium to reach a confluency of 70-80% to be seeded in a plurality of culture plates; preparing a caffeic acid phenethyl ester stock solution by dissolving the caffeic acid phenethyl ester in dimethyl sulfoxide DMSO; performing a microvesicle isolation from specialized skin cells; adding the caffeic acid phenethyl ester into a plurality of microvesicles; and separating the caffeic acid phenethyl ester loaded microvesicles from the caffeic acid phenethyl ester which is free in the solution and not loaded to a microvesicle.

Abstract: A production of a drug, wherein the drug is specific for SH-SY5Y neuroblastoma cancer by loading caffeic acid phenethyl ester (CAPE) to a plurality of microvesicles that a specialized skin cell leaves into a nutrient solution. The objective of the present invention is to provide a cell-specific targeted vesicle development by loading the CAPE to the plurality of microvesicles obtained as a result of culturing and subsequent specialization of a plurality of tissue cells; and to use the CAPE at lower concentrations compared to a state of the art applications to minimize a toxicity of the CAPE to both a plurality of cells other than a plurality of targeted cells and a body.